Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Phase II Trial of Pembrolizumab Plus Lenvatinib in Advanced Adrenal Cortical Carcinoma After Failure of Platinum- and Mitotane-Based Chemotherapy

NCT05036434 is registered in ClinicalTrials.gov with National Cancer Center, Korea as lead sponsor.

NCT NCT05036434
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05036434 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Phase II Trial of Pembrolizumab Plus Lenvatinib in Advanced Adrenal Cortical Carcinoma After Failure of Platinum- and Mitotane-Based Chemotherapy
Lead sponsor
National Cancer Center, Korea
Phase
Phase 2
Overall status
Active, not recruiting
Start date
November 15, 2021
Completion date
February 28, 2027
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adrenocortical carcinoma